Yan Zhou

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

Margaret Johnson, Princy Kumar, Jean‐Michel Molina et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 94 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients

Sergio Serrano‐Villar, Yan Zhou, Anthony Rodgers et al. · Journal of Antimicrobial Chemotherapy · 2016 · 30 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

Pedro Cahn, Paul E. Sax, Kathleen Squires et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2018 · 25 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies

Kathleen Squires, Linda‐Gail Bekker, Christine Katlama et al. · Open Forum Infectious Diseases · 2017 · 13 citations · Full text

Public Health, Infectious Diseases, Pharmacology +13